Cannabis Report
Lithium
Home > Boards > US Listed > Biotechs >

ARATANA THERAPEUTICS, INC. (PETX)

PETX RSS Feed
Add PETX Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 8/14/2018 10:32:48 PM - Followers: 36 - Board type: Free - Posts Today: 0
















Welcome to Aratana Therapeutics 

Aratana Therapeutics is a biopharmaceutical company positioned to deliver innovative prescription medicines that address significant medical needs for cats and dogs (companion animals). 

The company licenses proprietary, patent-protected compounds from human pharmaceutical and biotechnology companies.  Aratana’s team of veterinary drug development experts then advance these compounds through clinical studies designed expressly for demonstrating safety and efficacy in the target specie(s).  Aratana believes the development and commercialization of these therapeutics  will permit veterinarians and companion animal owners to manage pets' medical needs safely and effectively. 

Pets are our passion because pets are family.







About Aratana Therapeutics 


Company Overview 

Companion animals are living longer and therefore are at higher risk of developing an increasing number of medical conditions such as allergies, arthritis, diabetes, cancer and obesity; however, few treatment options exist for these conditions today.   

Aratana is positioned to address this need for better pet care by bringing human science to animal health and providing veterinarians with innovative new medicines that have been designed specifically for treating pets.   

Aratana’s unique “pet-centric” approach differs fundamentally from the current standard, which often involves adjusting the dose of marketed human drugs, which are only presumed to be safe and effective in animals based on human data and veterinary experience. There is significant demand amongst veterinarians and pet owners for higher quality medicines that have been specifically studied and approved by regulatory authorities for each species. Aratana’s team of drug development and commercial experts are dedicated to developing innovative treatments in accordance with regulatory standards to meet these needs. 

Mission and Strategy 

Aratana's mission is to find, develop and commercialize safe and effective therapeutics to enhance the quality of life and strengthen the bond between people and their pets. Our strategy is to become the leading provider of therapeutics developed and approved specifically for the treatment of unmet medical needs in pets. We intend to help shape and define the pet therapeutics market by identifying, acquiring and developing high-value commercial products for companion animals in a cost effective and efficient manner. 

Programs 

Aratana is currently developing several compounds for the large and growing pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence, and a recently licensed non-opioid local anesthetic for treating post-operative pain. These compounds, which are being developed individually for both cats and dogs, are supported by substantial safety and efficacy data and, if approved by regulatory authorities, could become best- or first-in-class products in the animal health industry. 


The company is actively identifying additional programs to in-license from human health companies in order to expand its development pipeline of animal medicines





Corporate Headquarters
1901 Olathe Blvd 
Kansas City, Kansas 66103
(913) 951-2132

Other Locations
200 Clarendon Street; 54th Floor 
Boston, Massachusetts 02116
(617) 425-9226

 

Business Development Contacts
Julia A. Stephanus 
Chief Commercial Officer
(913) 951-2139
juliaastephanus@aratana.com

Erick J. Lucera, CPA, CFA 
Vice President, Corporate Development
(913) 951-2136
erickjlucera@aratana.com

 

Investor and Media Contacts
Tiberend Strategic Advisors, Inc. 
35 West 35th Street; 11th Floor
New York, New York 10001
(212) 827-0020

Investors - Joshua Drumm, PhD 
(212) 375-2665
jdrumm@tiberend.com

Media - Andrew Mielach 
(212) 375-2694
amielach@tiberend.com

 

Transfer Agent and Registrar
American Stock Transfer & Trust Company, LLC. 
(800) 937-5449










Cannabis Report
Lithium
PETX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PETX News: Aratana Therapeutics to Present at CL King and Associates Best Ideas Conference 08/29/2018 08:30:00 AM
PETX News: Confidential Treatment Order (ct Order) 08/24/2018 02:51:26 PM
PETX News: Amended Statement of Beneficial Ownership (sc 13d/a) 08/20/2018 05:11:39 PM
PETX News: Statement of Changes in Beneficial Ownership (4) 08/14/2018 05:34:35 PM
PETX News: Statement of Changes in Beneficial Ownership (4) 08/10/2018 06:03:00 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#421   Invasion of the body snatchers. :-( terry hallinan 08/14/18 10:32:48 PM
#420   Invasion of the body snatchers. :-( terry hallinan 08/14/18 10:32:46 PM
#419   • Engaged Capital updates on its portfolio holdings biotech_researcher 08/14/18 05:27:55 PM
#418   Aratana Therapeutics (PETX) terry hallinan 08/13/18 08:27:39 AM
#417   Darn nice bounce from the earnings release low... biotech_researcher 08/07/18 09:57:24 AM
#416   Blue, Biotech; terry hallinan 08/03/18 04:42:10 PM
#415   Blue, I review Aratana’s PR, and your post biotech_researcher 08/03/18 10:45:36 AM
#414   Blue, my point is these sales numbers are biotech_researcher 08/03/18 09:36:43 AM
#413   Not confused at all. Subtract $3.7Mil to Elanco BlueRayn 08/03/18 09:26:24 AM
#412   I’m looking to re-enter PETX again. I bought biotech_researcher 08/03/18 06:32:30 AM
#411   Blue, you maybe confused as here is the biotech_researcher 08/03/18 05:42:00 AM
#410   With quarterly revenue declining in Q2 5% from terry hallinan 08/03/18 05:40:17 AM
#409   What? The qtrly rev drop was due to BlueRayn 08/03/18 05:20:36 AM
#408   With quarterly revenue declining in Q2 5% from biotech_researcher 08/02/18 10:42:36 PM
#407   New Fans Update. :-) terry hallinan 07/18/18 02:46:44 PM
#406   PETX appears to have no fans. terry hallinan 07/03/18 03:37:32 AM
#405   PETX appears to have no fans.. The sales biotech_researcher 07/02/18 10:39:39 AM
#404   Prostaglandin E2 Exerts Catabolic Effects in Osteoarthritis Cartilage: terry hallinan 06/20/18 03:24:25 PM
#403   Aratana Therapeutics Files for FDA Approval of NOCITA® terry hallinan 06/01/18 11:10:57 AM
#402   Yes, I wondered about Lowell as well. But, biotech_researcher 05/21/18 08:29:01 PM
#401   Aratana Therapeutics Appoints Craig Barbarosh and Lowell Robins terry hallinan 05/21/18 06:20:04 PM
#400   Not a single large successful company was a sellout. terry hallinan 05/06/18 12:47:19 PM
#399   PETX- This is what PETX needs.They need to biotech_researcher 05/05/18 10:12:57 PM
#398   Quote:”The Activist Spotlight Aratana Therapeutics (PETX) Business: develops a BlueRayn 05/05/18 02:48:18 PM
#397   Engage Capital seeks 3 BD Seats and wants BlueRayn 05/05/18 02:46:37 PM
#396   Apologize in advance for length of message but terry hallinan 05/05/18 01:53:11 PM
#395   “So why the dreadful headlines?” terry hallinan 05/04/18 11:08:32 AM
#394   “So why the dreadful headlines?” Hmmm, that is a biotech_researcher 05/04/18 08:52:49 AM
#393   There are obviously other treatment options available. terry hallinan 05/04/18 08:41:16 AM
#392   Sales are going nowhere, it appears. $4 million biotech_researcher 05/03/18 09:22:40 PM
#391   Aratana Therapeutics Reports First Quarter 2018 Financial Resul terry hallinan 05/03/18 08:49:44 PM
#390   terry hallinan 04/11/18 10:19:41 PM
#389   Lots up, Madman, but I am deeply prejudiced. terry hallinan 04/04/18 05:25:16 PM
#388   My bad, somethings up this thing is starting madmanmartinwins 04/04/18 02:13:44 PM
#387   Relax dude, the market is closed today... Good Friday Traderbx 03/30/18 11:39:06 AM
#386   No trades today? I feel a meltdown in madmanmartinwins 03/30/18 10:45:59 AM
#385   Stifel Calls Aratana Therapeutics a 'Buy' on Entyce, terry hallinan 03/27/18 05:09:41 PM
#384   From transcript of PETX teleconference on 4thQ results 3/14/18: terry hallinan 03/18/18 08:10:02 AM
#383   terry hallinan 03/18/18 08:10:01 AM
#382   “Takes all kinds actually” How thankfully right you are... biotech_researcher 03/15/18 06:52:10 AM
#381   I expect you probably have a academia background terry hallinan 03/15/18 12:31:07 AM
#380   Terry Hallinan, I expect you probably have a biotech_researcher 03/14/18 09:32:27 PM
#379   Sell off was technical. But this stock is BlueRayn 03/14/18 07:45:15 PM
#378   Hard to understand today's sell off. Bickema 03/14/18 04:55:26 PM
#377   Biotech_researcher, Terry Hallinan, I expect with the Q4 res terry hallinan 03/14/18 02:21:03 PM
#376   Terry Hallinan, I expect with the Q4 results biotech_researcher 03/14/18 10:21:22 AM
#375   Beyond the horizon terry hallinan 03/13/18 05:31:37 PM
#374   Biotech Researcher, terry hallinan 03/04/18 08:11:52 PM
#373   So, PETX received $5.4-$2.2 or $3.2 million of biotech_researcher 03/04/18 08:56:54 AM
#372   When Aratana can exhibit a solid ramp up terry hallinan 03/04/18 12:45:59 AM
PostSubject